Concepedia

Mark D. Hjelmeland

MD

Statistics

Publications

7

Citations

926

H-Index

7

Active since

2003

Affiliations

Duke Medical Center(Current)

Duke University Hospital

Duke University

Immunovaccine (Canada)

Institute of Neurobiology

Mark D. Hjelmeland is an author at Duke Medical Center specializing in medicine, oncology, and molecular oncology.

Publications per year

2003–2007

7

Publications

7

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition

Ranjit K. Goudar, Qing Shi, Mark D. Hjelmeland et al. · Molecular Cancer Therapeutics · 2005 · 245 citations · Full text

Medicine, Oncology, Pharmacology +17

SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.

Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee et al. · PubMed · 2004 · 192 citations

Medicine, Oncology, Pharmacology +17

SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility

Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee et al. · Molecular Cancer Therapeutics · 2004 · 174 citations · Full text

Medicine, Oncology, Pharmacology +17

Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model

Jeremy N. Rich, Qing Shi, Mark D. Hjelmeland et al. · Journal of Biological Chemistry · 2003 · 147 citations · Full text

Medicine, Cancer Biology, Oncology +15

Regulation of E2A Activities by Histone Acetyltransferases in B Lymphocyte Development

Curtis P. Bradney, Mark D. Hjelmeland, Yasuhiko Komatsu et al. · Journal of Biological Chemistry · 2003 · 82 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

1–5 of 7